Summary
Updated Aug 31, 2026
Erik C. Emerson is Chief Executive Officer, Director of Apimeds Pharmaceuticals US, Inc. (APUS). 1 SEC Form 4 filing on record, dated 15 October 2025.
Trading Pattern
InsiderAlpha's records for Erik C. Emerson go back to 2025: 1 primary Form 4 filing, an average of 0.5 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Other Insiders Active in the Same Sector
No other insider has filed at Erik C. Emerson's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- LILLY ENDOWMENT INC - $3.10B of LLY open-market activity in the last 12 months
- KKR Phoenix Aggregator L.P. - $2.09B of BTSG open-market activity in the last 12 months
- KKR Group Partnership L.P. - $2.09B of BTSG open-market activity in the last 12 months
- WARBURG PINCUS CO. - $1.30B of SHC open-market activity in the last 12 months
- GTCR INVESTMENT XI LLC - $760.39M of SHC open-market activity in the last 12 months
- Martine A. Rothblatt - $703.37M of UTHR open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Erik C. Emerson?
Erik C. Emerson is a corporate insider, tracked as Chief Executive Officer, Director of Apimeds Pharmaceuticals US, Inc. (APUS). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
When did Erik C. Emerson last file a Form 4?
The only primary Form 4 on record is dated 15 October 2025.
Where can I see all of Erik C. Emerson's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Erik C. Emerson and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial